Data ExclusivitiesTRIPS Data Exclusivity and Trips Flexibilities: Going Back to the BasicsAugust 18, 2020 The COVID-19 pandemic has provided enough food for thought to reconsider public healthcare issues and…Sonal Singh Data ExclusivitiesPatents Is it Time to Do Away with Data Exclusivity?July 8, 2020 If there is a lesson from COVID-19, it is the need to look at the…Srividhya RagavanJonathan Kimball Data ExclusivitiesPatents Drug Exclusivities in the US: Is it Justified? (Part 2 of 2)June 25, 2020 This is Part 2 of a two-part Article. In Part I, I dealt with Henry…Bhavik Shukla Data ExclusivitiesPatents Drug Exclusivities in the US: Is it justified? (Part 1 of 2)June 25, 2020 This is Part 1 of a two-part Article. Data and market exclusivities, often termed as…Bhavik Shukla Latest Posts Search Search Blog Front Page BLOG POSTS The Under-Appreciated Virtue of Transparency in Combatting COVID-19 The India South Africa Proposal: Strengths & Weaknesses Assuring Social Justice for Access to COVID-19 Vaccines: Part II Fixing the Broken Supply Chain Through Information Assuring Social Justice for Access to COVID-19 Vaccines: Part 1 Fixing the Broken Disclosure System Patents and Trade: Opportunities and Challenges in the Global Healthcare Market CATEGORIES COVID-19 13 Data Exclusivities 4 Deceptive Claims 1 Exhaustion 2 Experimental Use 1 IPAB 1 Patent Pools 2 Patents 15 Right to Health 1 TAMU 1 Trade Policy 1 TRIPS 13 TRIPS Flexibilities 2 Vaccines 1 Voluntary Licenses 1
Data ExclusivitiesPatents Is it Time to Do Away with Data Exclusivity?July 8, 2020 If there is a lesson from COVID-19, it is the need to look at the…Srividhya RagavanJonathan Kimball Data ExclusivitiesPatents Drug Exclusivities in the US: Is it Justified? (Part 2 of 2)June 25, 2020 This is Part 2 of a two-part Article. In Part I, I dealt with Henry…Bhavik Shukla Data ExclusivitiesPatents Drug Exclusivities in the US: Is it justified? (Part 1 of 2)June 25, 2020 This is Part 1 of a two-part Article. Data and market exclusivities, often termed as…Bhavik Shukla Latest Posts Search Search Blog Front Page BLOG POSTS The Under-Appreciated Virtue of Transparency in Combatting COVID-19 The India South Africa Proposal: Strengths & Weaknesses Assuring Social Justice for Access to COVID-19 Vaccines: Part II Fixing the Broken Supply Chain Through Information Assuring Social Justice for Access to COVID-19 Vaccines: Part 1 Fixing the Broken Disclosure System Patents and Trade: Opportunities and Challenges in the Global Healthcare Market CATEGORIES COVID-19 13 Data Exclusivities 4 Deceptive Claims 1 Exhaustion 2 Experimental Use 1 IPAB 1 Patent Pools 2 Patents 15 Right to Health 1 TAMU 1 Trade Policy 1 TRIPS 13 TRIPS Flexibilities 2 Vaccines 1 Voluntary Licenses 1
Data ExclusivitiesPatents Drug Exclusivities in the US: Is it Justified? (Part 2 of 2)June 25, 2020 This is Part 2 of a two-part Article. In Part I, I dealt with Henry…Bhavik Shukla Data ExclusivitiesPatents Drug Exclusivities in the US: Is it justified? (Part 1 of 2)June 25, 2020 This is Part 1 of a two-part Article. Data and market exclusivities, often termed as…Bhavik Shukla Latest Posts Search Search Blog Front Page BLOG POSTS The Under-Appreciated Virtue of Transparency in Combatting COVID-19 The India South Africa Proposal: Strengths & Weaknesses Assuring Social Justice for Access to COVID-19 Vaccines: Part II Fixing the Broken Supply Chain Through Information Assuring Social Justice for Access to COVID-19 Vaccines: Part 1 Fixing the Broken Disclosure System Patents and Trade: Opportunities and Challenges in the Global Healthcare Market CATEGORIES COVID-19 13 Data Exclusivities 4 Deceptive Claims 1 Exhaustion 2 Experimental Use 1 IPAB 1 Patent Pools 2 Patents 15 Right to Health 1 TAMU 1 Trade Policy 1 TRIPS 13 TRIPS Flexibilities 2 Vaccines 1 Voluntary Licenses 1
Data ExclusivitiesPatents Drug Exclusivities in the US: Is it justified? (Part 1 of 2)June 25, 2020 This is Part 1 of a two-part Article. Data and market exclusivities, often termed as…Bhavik Shukla
